5 recruiting, 1 completed, 1 not yet recruiting. 3 Phase 1, 2 Phase 2, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 3 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow CVAD protocol: new trials by email Literature Review of CVAD protocol trials Research Report on CVAD protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia Blinatumomab, Induction Chemotherapy, Hyper-CVAD - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 101 | 2025-04-01 | 2026-05-04 |
| A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias Venetoclax, Hyper-CVAD - Refractory Acute Leukemia, Relapsed Acute Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 22 | 2025-02-18 | 2026-09-15 |
| Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Etoposide, Cytarabine, PEG-rhG-CSF - Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2025-12-04 |
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD - Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-11 | 2026-08-10 |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2023-05-01 | 2026-03-06 |
| A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy Hyper-CVAD, Sirolimus - Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 7 | 2010-07-01 | 2025-05-04 |
Burkitt Lymphoma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (2) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
M.D. Anderson Cancer Center (2) · Amgen (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · The Affiliated People's Hospital of Ningbo University (1) · The First Affiliated Hospital of Soochow University (1)
United States (4) · China (2)
Bijal Shah, MD (1) · David McCall, MD (1) · Elias Jabbour, MD (1) · Margaret Kasner, MD (1) · Peipei Ye (1) · Suning Chen (1)
2025 (1)